Literature DB >> 2833610

Efficient transcription, not translation, is dependent on adenovirus tripartite leader sequences at late times of infection.

F V Alonso-Caplen1, M G Katze, R M Krug.   

Abstract

To determine whether the tripartite leader is required for efficient translation in adenovirus-infected cells at late times of infection, we constructed recombinant adenoviruses containing the influenza virus nucleocapsid protein (NP) gene expressed under the control of the adenovirus major late promoter (MLP). We chose the NP gene because previous results showed that the influenza virus NP mRNA was an extremely effective initiator of translation in cells which were superinfected with influenza virus at late times of adenovirus infection (M. G. Katze, B. M. Detjen, B. Safer, and R. M. Krug, Mol. Cell. Biol. 6:1741-1750, 1986). The NP gene in the adenovirus recombinants was inserted downstream of an MLP that replaced part of the early (E1A) region. The resulting NP mRNAs either lacked any tripartite leader sequences or contained at their 5' ends various portions of the tripartite leader: 33, 172, or all 200 nucleotides of the leader. The relative amounts of the NP protein synthesized by the recombinants were directly proportional to the amounts of the NP mRNA made, indicating that the presence of 5' tripartite leader sequences did not enhance the translation of NP mRNA. In addition, the sizes of the polysomes containing NP mRNA were not increased by the presence of tripartite leader sequences, indicating that the initiation of translation was not enhanced by these sequences. On the other hand, the presence of tripartite leader sequences immediately downstream of the MLP did enhance the transcription of the inserted NP gene, as shown by Northern (RNA) analysis of in vivo NP mRNA levels and by in vitro runoff assays with isolated nuclei. Our results indicate that more than 33 nucleotides of the first leader segment of the tripartite leader are required for optimal transcription from the MLP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833610      PMCID: PMC253188          DOI: 10.1128/JVI.62.5.1606-1616.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Purification of influenza viral complementary RNA: its genetic content and activity in wheat germ cell-free extracts.

Authors:  P R Etkind; R M Krug
Journal:  J Virol       Date:  1975-12       Impact factor: 5.103

2.  The cytoskeletal framework and poliovirus metabolism.

Authors:  R Lenk; S Penman
Journal:  Cell       Date:  1979-02       Impact factor: 41.582

Review 3.  How do eucaryotic ribosomes select initiation regions in messenger RNA?

Authors:  M Kozak
Journal:  Cell       Date:  1978-12       Impact factor: 41.582

4.  Rates of initiation of protein synthesis by two purified species of vesicular stomatitis virus messenger RNA.

Authors:  H F Lodish; S Froshauer
Journal:  J Biol Chem       Date:  1977-12-25       Impact factor: 5.157

5.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

6.  Downstream sequences affect transcription initiation from the adenovirus major late promoter.

Authors:  S L Mansour; T Grodzicker; R Tjian
Journal:  Mol Cell Biol       Date:  1986-07       Impact factor: 4.272

7.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

8.  Nucleotide sequence analysis of the leader segments in a cloned copy of adenovirus 2 fiber mRNA.

Authors:  S Zain; J Sambrook; R J Roberts; W Keller; M Fried; A R Dunn
Journal:  Cell       Date:  1979-04       Impact factor: 41.582

9.  Intracellular uncoating of type 5 adenovirus deoxyribonucleic acid.

Authors:  W C Lawrence; H S Ginsberg
Journal:  J Virol       Date:  1967-10       Impact factor: 5.103

10.  Spliced segments at the 5' terminus of adenovirus 2 late mRNA.

Authors:  S M Berget; C Moore; P A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

View more
  20 in total

Review 1.  Translational control of viral gene expression in eukaryotes.

Authors:  M Gale; S L Tan; M G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

2.  Identification of a novel downstream binding protein implicated in late-phase-specific activation of the adenovirus major late promotor.

Authors:  G Mondesert; C Tribouley; C Kedinger
Journal:  Nucleic Acids Res       Date:  1992-08-11       Impact factor: 16.971

3.  Cooperation between upstream and downstream elements of the adenovirus major late promoter for maximal late phase-specific transcription.

Authors:  G Mondésert; C Kédinger
Journal:  Nucleic Acids Res       Date:  1991-06-25       Impact factor: 16.971

4.  Nucleoplasmic and nucleolar distribution of the adenovirus IVa2 gene product.

Authors:  P Lutz; F Puvion-Dutilleul; Y Lutz; C Kedinger
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

5.  Properties of the adenovirus IVa2 gene product, an effector of late-phase-dependent activation of the major late promoter.

Authors:  P Lutz; C Kedinger
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

6.  The product of the adenovirus intermediate gene IX is a transcriptional activator.

Authors:  P Lutz; M Rosa-Calatrava; C Kedinger
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  A Mutation in the UL24 Gene Abolishes Expression of the Newly Identified UL24.5 Protein of Herpes Simplex Virus 1 and Leads to an Increase in Pathogenicity in Mice.

Authors:  Slimane Dridi; Nicolas Richerioux; Carmen Elena Gonzalez Suarez; Marion Vanharen; Carolina Sanabria-Solano; Angela Pearson
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

8.  Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.

Authors:  Rachmat Hidajat; Seraphin Kuate; David Venzon; Vaniambadi Kalyanaraman; Irene Kalisz; James Treece; Ying Lian; Susan W Barnett; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2010-04-09       Impact factor: 3.641

9.  RNA-binding properties of a translational activator, the adenovirus L4 100-kilodalton protein.

Authors:  D Riley; S J Flint
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Modification of eukaryotic initiation factor 4F during infection by influenza virus.

Authors:  D Feigenblum; R J Schneider
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.